Can surgery or radiation boost lung cancer control after targeted therapy?
NCT ID NCT07073365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding surgery or radiation to the main tumor can help people with advanced EGFR-mutant lung cancer who have already responded to a combination of osimertinib and chemotherapy. About 70 adults will receive local therapy and be followed to see how long the cancer stays under control. The goal is to improve outcomes without needing lifelong medication changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMAL GROWTH FACTOR RECEPTOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pusan National University Hospital
RECRUITINGBusan, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?